Bridgebio Pharma Stock Price, News & Analysis

BridgeBio Pharma (Nasdaq: BBIO) reported its third quarter 2021 financial results, revealing a net loss of $155.9 million, compared to a net loss of $115.9 million in Q3 2020. Revenue decreased to $2.3 million from $8.1 million year-over-year. Operating costs rose to $151.8 million, driven by increased R&D expenses. The company holds $599.6 million in cash and equivalents, down from $607.1 million at year-end 2020. BridgeBio continues to advance its pipeline, with 30 programs and 20 clinical trials. Notably, it received FDA approvals for two drugs earlier this year.

BridgeBio Pharma, Inc. (Nasdaq: BBIO) announced the dosing of the first patient in the CANaspire Phase 1/2 trial for BBP-812, a gene therapy for Canavan disease, which affects approximately 1,000 children in the U.S. and EU. This investigational therapy aims to restore survival and motor function in pediatric patients. Currently, no approved therapies exist for this fatal disease. The trial evaluates safety, tolerability, and pharmacodynamic activity, with results expected in 2022. BBP-812 has received multiple designations from the FDA and EMA, highlighting its potential.

BridgeBio Pharma (Nasdaq: BBIO) announced two new collaborations with Columbia University and Mount Sinai to develop therapies for genetic diseases and cancers. This strategic partnership enhances BridgeBio's existing network of over 25 collaborations aimed at rapidly progressing therapeutic options for patients. Both institutions will focus on leveraging early-stage innovations to expedite research into potential treatments, continuing BridgeBio's commitment to driving advancements in genetic medicine.

BridgeBio Pharma (Nasdaq: BBIO) reported significant advancements in its KRAS cancer portfolio during its second annual R&D Day on October 12, 2021. The company unveiled the discovery of next-generation G12C dual inhibitors for KRAS cancers, showing over 500-fold potency compared to first-generation inhibitors. BridgeBio also introduced new gene therapy programs, including BBP-818 for classic galactosemia, and shared updates on its cardiorenal and Mendelian programs. In addition, the launch of BridgeBioX aims to enhance early-stage research and innovation in genetic diseases.

BridgeBio Pharma (Nasdaq: BBIO) announced promising preclinical data for its SHP2 inhibitor, BBP-398, targeting non-small cell lung cancer (NSCLC). The data, presented at the AACR-NCI-EORTC Conference, reveals BBP-398's potential as a combination agent with KRAS and EGFR inhibitors. The company is advancing a Phase 1 trial for patients with solid tumors with MAPK pathway mutations. The anticipated continuous once-daily dosing and strong preclinical efficacy could position BBP-398 as a leading treatment option for RAS-driven cancers. Further insights will be shared at the virtual R&D Day on October 12, 2021.

BridgeBio Pharma, Inc. (Nasdaq: BBIO) will hold its second R&D Day on October 12, 2021, at 8:30 a.m. ET, showcasing its pipeline and new programs. The event will feature key executives, including founder and CEO Neil Kumar, discussing 14 clinical programs and over 30 total pipeline programs targeting genetic diseases and cancers. A focus will be on acoramidis, an investigational therapy for transthyretin amyloidosis (ATTR), with topline results expected in late 2021 and 2023. The webcast will be accessible through BridgeBio's investor website.

BridgeBio Pharma (Nasdaq: BBIO) reported updated results from its ongoing Phase 2b study of encaleret for treating Autosomal Dominant Hypocalcemia Type 1 (ADH1). The study involved 13 participants, with encaleret normalizing mean blood calcium levels and 24-hour urine calcium excretion within five days. No serious adverse events were reported, showcasing the drug's tolerability. The company plans to engage regulatory authorities for a Phase 3 study, aiming to develop the first approved therapy for ADH1. The ongoing research highlights a significant unmet medical need in this rare condition.

BridgeBio Pharma (Nasdaq: BBIO) announced that the FDA has granted Fast Track designation for BBP-418, aimed at treating Limb-girdle Muscular Dystrophy Type 2i (LGMD2i). This designation will expedite the development and review process for the therapy, addressing a critical unmet medical need for patients with this rare genetic condition. With 7,000 patients affected by LGMD2i, BBP-418 represents a significant advancement in BridgeBio's pipeline, which includes multiple ongoing programs in genetic diseases and cancers.

BridgeBio Pharma announced on September 2, 2021, the granting of restricted stock units totaling 61,210 shares to 29 new employees. This initiative aims to incentivize new hires and is in accordance with Nasdaq Listing Rule 5635(c)(4). These awards were made under the 2019 Inducement Equity Plan, which was approved in November 2019. BridgeBio focuses on developing transformative medicines for genetic diseases and cancers, with over 30 development programs currently in progress.